Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Schett
Steven L Teitelbaum

Showing results (291-300 of 1,160) with videos related to

Pageof 116
Sort By:
Frontiers in Endocrinology|August 23, 2021
RANKL-Induced Btn2a2 - A T Cell Immunomodulatory Molecule - During Osteoclast Differentiation Fine-Tunes Bone ResorptionMichael Frech, Gregor Schuster, Fabian T Andes, et al.
European Journal of Radiology|January 17, 2025
Impact of intravenous CT contrast agents on internal calibration techniques to determine trabecular BMD of the lumbar spineStefan Bartenschlager, Alexander Cavallaro, Tobias Pogarell, et al.
Endocrinology|November 26, 2002
Tyrosines 559 and 807 in the cytoplasmic tail of the macrophage colony-stimulating factor receptor play distinct roles in osteoclast differentiation and functionXu Feng, Sunao Takeshita, Noriyuki Namba, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 5, 2006
SHIP1 negatively regulates proliferation of osteoclast precursors via Akt-dependent alterations in D-type cyclins and p27Ping Zhou, Hideki Kitaura, Steven L Teitelbaum, et al.
Annals of the Rheumatic Diseases|May 31, 2011
Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosionStephanie Finzel, Juergen Rech, Sarah Schmidt, et al.
Arthritis and Rheumatism|May 28, 2010
Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritisDaniel Cejka, Silvia Hayer, Birgit Niederreiter, et al.
Arthritis and Rheumatism|December 16, 2003
Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockadeKurt Redlich, Georg Schett, Günter Steiner, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|December 3, 2024
Colchicine inhibits monosodium urate crystal-mediated inflammation by influencing F-actin formationLingjiang Zhu, Yuqi Wang, Lizhen Shan, et al.
Nature Reviews. Rheumatology|May 5, 2022
Psoriatic arthritis from a mechanistic perspectiveGeorg Schett, Proton Rahman, Christopher Ritchlin, et al.
Frontiers in Immunology|May 27, 2014
Tumor immunotherapy: lessons from autoimmunityChristian Maueröder, Luis Enrique Munoz, Ricardo Alfredo Chaurio, et al.
Pageof 116

Showing results (291-300 of 1,160) with videos related to

Sort By:
Pageof 116
Frontiers in Endocrinology|August 23, 2021
RANKL-Induced Btn2a2 - A T Cell Immunomodulatory Molecule - During Osteoclast Differentiation Fine-Tunes Bone ResorptionMichael Frech, Gregor Schuster, Fabian T Andes, et al.
European Journal of Radiology|January 17, 2025
Impact of intravenous CT contrast agents on internal calibration techniques to determine trabecular BMD of the lumbar spineStefan Bartenschlager, Alexander Cavallaro, Tobias Pogarell, et al.
Endocrinology|November 26, 2002
Tyrosines 559 and 807 in the cytoplasmic tail of the macrophage colony-stimulating factor receptor play distinct roles in osteoclast differentiation and functionXu Feng, Sunao Takeshita, Noriyuki Namba, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 5, 2006
SHIP1 negatively regulates proliferation of osteoclast precursors via Akt-dependent alterations in D-type cyclins and p27Ping Zhou, Hideki Kitaura, Steven L Teitelbaum, et al.
Annals of the Rheumatic Diseases|May 31, 2011
Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosionStephanie Finzel, Juergen Rech, Sarah Schmidt, et al.
Arthritis and Rheumatism|May 28, 2010
Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritisDaniel Cejka, Silvia Hayer, Birgit Niederreiter, et al.
Arthritis and Rheumatism|December 16, 2003
Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockadeKurt Redlich, Georg Schett, Günter Steiner, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|December 3, 2024
Colchicine inhibits monosodium urate crystal-mediated inflammation by influencing F-actin formationLingjiang Zhu, Yuqi Wang, Lizhen Shan, et al.
Nature Reviews. Rheumatology|May 5, 2022
Psoriatic arthritis from a mechanistic perspectiveGeorg Schett, Proton Rahman, Christopher Ritchlin, et al.
Frontiers in Immunology|May 27, 2014
Tumor immunotherapy: lessons from autoimmunityChristian Maueröder, Luis Enrique Munoz, Ricardo Alfredo Chaurio, et al.
Pageof 116